Tessera Therapeutics, a Somerville, MA-based biotechnology company providing a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, received an investment from Bill & Melinda Gates Foundation.
The funding included an initial investment, with potential total investment of up to $50M.
The company intends to use the funds to advance a SCD treatment and further its objectives to develop genetic medicines that are accessible globally.
Led by CEO Michael Severino, Tessera is developing Gene Writers™ for SCD designed to enable a true correction of the sickle mutation to wild-type with one-time intravenous administration in vivo, without the need for complex stem cell mobilization or toxic chemotherapy conditioning. Critical in enabling in vivo therapies, the company is leveraging its proprietary non-viral delivery platform to develop lipid nanoparticles targeting delivery of Gene Writers to long-term hematopoietic stem cells.
FinSMEs
18/12/2024